Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564062 | 1.00 | KEAP1 (0.60) | KEAP1KDM4EALDH1A1EGFRSRC | |
| SCHEMBL7605310 | 0.98 | KEAP1 (0.58) | KEAP1KDM4EALDH1A1EGFRSRC | |
| SCHEMBL7605316 | 0.98 | KEAP1 (0.58) | KEAP1KDM4EALDH1A1EGFRSRC | |
| Phenyl Propionic Acid SCHEMBL7826574 | 0.92 | KEAP1 (0.76) | KEAP1KDM4EALDH1A1FFAR1HDAC3 | |
| SCHEMBL9782880 | 0.90 | FFAR1 (0.68) | KEAP1KDM4EALDH1A1EGFRSRC | |
| SCHEMBL11987690 | 0.90 | EGFR (0.50) | KEAP1KDM4EALDH1A1EGFRSRC | |
| SCHEMBL9426100 | 0.90 | ALDH1A1 (0.50) | KEAP1KDM4EALDH1A1EGFRSRC | |
| SCHEMBL9782874 | 0.88 | KEAP1 (0.59) | KEAP1KDM4EALDH1A1EGFRSRC | |
| SCHEMBL9782888 | 0.87 | RXFP1 (0.53) | KEAP1KDM4EALDH1A1EGFRSRC | |
| SCHEMBL28613421 | 0.86 | HDAC3 (0.63) | KEAP1KDM4EALDH1A1EGFRFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116514633-A | Synthesis method of 3,3' - (anthracene-9, 10-diyl) dipropionic acid | 上海麦克林生化科技股份有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-108530243-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-108546224-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-108530244-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-105016941-A | Process for the manufacture of nitriles and their corresponding amines | SINOPEC YANGZI PETROCHEMICAL | 2015-11-04 | — | — | CN | claimed |
| CN-105016945-A | Process for the manufacture of nitriles and their corresponding amines | SINOPEC YANGZI PETROCHEMICAL | 2015-11-04 | — | — | CN | claimed |
| CN-105001033-A | Process for the manufacture of nitriles and their corresponding amines | SINOPEC YANGZI PETROCHEMICAL | 2015-10-28 | — | — | CN | claimed |
| CN-1875030-A | Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular disease | SCRIPPS RES INSITTUTE (US) | 2006-12-06 | — | — | CN | claimed |
| US-20060217359-A1 | Therapeutic procedures | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | claimed |
| EP-1670812-A2 | OZONATION PRODUCTS OF CHOLESTEROL FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND/OR CARDIOVASCULAR DISEASES | The Scripps Research Institute (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050085557-A1 | Oxidation of cholesterol in atherosclerosis plaque; cytotoxic | SCRIPPS RESEARCH INSTITUTE, THE | 2005-04-21 | — | — | US | claimed |
| WO-2005023830-A2 | OZONATION PRODUCTS OF CHOLESTEROL FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND/OR CARDIOVASCULAR DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-03-17 | — | — | WO | claimed |
| JP-7076511-A | — | — | None | — | — | JP | disclosed |
| JP-7069855-A | — | — | None | — | — | JP | disclosed |
| JP-7069856-A | — | — | None | — | — | JP | disclosed |
| US-12433870-B2 | Supramolecular photoprotection of a photosensitizer | NORTHWESTERN UNIVERSITY (US) | 2025-10-07 | — | — | US | disclosed |
| JP-H0776511-A | COSMETIC | TOYOBO CO LTD | 1995-03-20 | — | — | JP | disclosed |
| JP-H0769855-A | COSMETIC | TOYOBO CO LTD | 1995-03-14 | — | — | JP | disclosed |
| JP-H0769856-A | COSMETIC | TOYOBO CO LTD | 1995-03-14 | — | — | JP | disclosed |
| EP-0515194-A2 | Assay methods utilizing induced luminescence | BEHRINGWERKE Aktiengesellschaft (DE) | 1992-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433870-B2 | Supramolecular photoprotection of a photosensitizer | PCNA, HAVCR2, CD47 | KEAP1 1318/4885KDM4E 4837/4885ALDH1A1 2875/4885 |
| US-20050085557-A1 | Oxidation of cholesterol in atherosclerosis plaque; cytotoxic | APOB, LDLR, CETP | KEAP1 452/4885KDM4E 4771/4885ALDH1A1 2866/4885 |
| US-20060217359-A1 | Therapeutic procedures | APOB, LIPA, CETP | KEAP1 563/4885KDM4E 4794/4885ALDH1A1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.